Equities
Health CarePharmaceuticals and Biotechnology
  • Price (USD)10.04
  • Today's Change-0.313 / -3.02%
  • Shares traded9.95k
  • 1 Year change+43.39%
  • Beta1.6587
Data delayed at least 15 minutes, as of Nov 05 2024 20:59 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Bavarian Nordic A/S is a Denmark-based biotechnology company engaged in manufacturing of pharmaceutical preparations. The Company is involved in research and development innovations, production and commercialization of life-saving vaccines based on viral vectors for the delivery of antigens targeting infectious diseases. Bavarian Nordic A/S offers travel health products including cholera, rabies, tick-borne encephalitis and typhoid vaccines, as well as vaccines sold and distributed in selected markets on behalf of third parties. The Company deals with vaccines aimed at improving public health and preparedness. Bavarian Nordic A/S focuses on vaccine solutions that help address the threat of infectious diseases. The Company operates worldwide.

  • Revenue in USD (TTM)887.30m
  • Net income in USD103.19m
  • Incorporated1992
  • Employees1.38k
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Ocular Therapeutix Inc61.10m-138.36m1.60bn267.00--4.23--26.21-1.09-1.090.52492.430.1912.362.12228,827.70-43.26-46.70-47.93-54.1890.8489.36-226.46-228.6516.55-11.300.1509--13.4996.60-13.65--26.37--
Harrow Inc154.15m-33.58m1.63bn315.00--27.78--10.55-0.9508-0.95084.381.650.5814.954.39489,352.40-12.66-10.86-14.77-12.7171.1670.75-21.78-15.352.43-0.35180.7608--46.9525.77-73.30--143.88--
Tarsus Pharmaceuticals Inc83.37m-150.07m1.76bn244.00--6.97--21.08-4.43-4.432.436.630.2947--5.36341,696.70-53.05-31.56-60.10-33.8292.50---180.00-242.596.99--0.221---32.42---118.86--279.39--
Harmony Biosciences Holdings Inc681.88m122.63m1.88bn246.0015.643.1612.832.762.112.1111.7510.460.799424.269.172,771,866.0014.387.4617.129.0878.6580.5817.9810.463.20--0.23450.0032.93---28.99---25.31--
Endo Inc-100.00bn-100.00bn1.91bn3.00k--1.04----------23.99------------------------1.52--0.5697---13.25--15.87------
Supernus Pharmaceuticals Inc630.16m5.24m1.91bn652.00392.851.9921.193.030.08830.088311.3917.390.48310.92564.36966,507.700.40164.950.51176.4188.3488.610.831412.841.69--0.00---8.958.24-97.83-58.81-8.17--
Ligand Pharmaceuticals Inc133.48m42.14m2.01bn58.0049.542.5726.0515.092.222.227.3342.820.16430.47894.082,301,345.005.1912.325.3512.9991.8281.6531.5780.3215.81--0.00002---33.09-12.181,131.21-17.8642.63--
Vericel Corp214.52m789.00k2.18bn314.002,346.388.92366.3610.140.01890.01894.464.970.6244.414.97683,184.700.2295-3.070.2595-3.5070.4267.870.3678-4.494.16--0.0008--20.1716.8080.96--59.35--
Bavarian Nordic A/S - ADR887.30m103.19m2.45bn1.38k23.501.5912.892.760.44040.44043.816.500.41571.505.10643,438.304.83--6.24--56.91--11.63--0.9311--0.0118--124.14--524.66------
Amphastar Pharmaceuticals Inc712.89m166.52m2.46bn1.76k16.123.4711.223.453.143.1413.4514.570.49682.856.04404,821.7011.719.4213.5411.5654.6847.8323.5615.232.637.420.45150.0029.1416.9450.51---4.00--
Twist Bioscience Corp295.21m-220.31m2.46bn919.00--5.01--8.35-3.81-3.815.128.390.40765.428.56321,229.60-30.42-30.50-33.85-33.8440.5336.02-74.63-113.334.52--0.00--20.4157.336.08--49.76--
Catalyst Pharmaceuticals Inc434.48m68.15m2.58bn167.0040.774.2424.655.940.53350.53353.715.140.75544.038.692,601,647.0011.8525.4213.5629.8186.6785.6315.6930.874.94--0.000.0085.90280.39-14.05--20.21--
Amneal Pharmaceuticals Inc2.60bn-174.62m2.60bn7.70k----28.281.00-0.6224-0.622410.09-0.18570.72063.003.60337,401.60-3.69-4.80-4.93-5.9335.0434.76-5.13-9.000.81651.241.00--8.207.5635.38---6.55--
PTC Therapeutics, Inc.900.45m-479.52m3.11bn988.00------3.45-6.32-6.3211.84-12.750.55342.164.94911,390.70-29.47-26.71-44.23-33.4692.3593.94-53.25-83.802.17-1.121.70--34.2028.78-12.09--32.00--
Data as of Nov 05 2024. Currency figures normalised to Bavarian Nordic A/S's reporting currency: US Dollar USD

Institutional shareholders

0.00%Per cent of shares held by top holders
HolderShares% Held
RhumbLine Advisers LPas of 30 Jun 2024538.000.00%
Data from 30 Jun 2024 - 30 Jun 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.